C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 123 filers reported holding C4 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,007,157 | -32.4% | 2,692,020 | 0.0% | 0.46% | -43.9% |
| Q2 2023 | $7,403,055 | -1.2% | 2,692,020 | +12.8% | 0.82% | +6.1% |
| Q1 2023 | $7,495,243 | -48.0% | 2,387,020 | -2.2% | 0.78% | -62.4% |
| Q4 2022 | $14,400,974 | +13.9% | 2,440,843 | +69.3% | 2.07% | +20.3% |
| Q3 2022 | $12,642,000 | +493.2% | 1,441,513 | +410.0% | 1.72% | +417.5% |
| Q2 2022 | $2,131,000 | -47.3% | 282,640 | +69.5% | 0.33% | -36.4% |
| Q1 2022 | $4,045,000 | -77.6% | 166,736 | -70.3% | 0.52% | -71.1% |
| Q4 2021 | $18,068,000 | -46.1% | 561,122 | -25.2% | 1.81% | -65.4% |
| Q3 2021 | $33,538,000 | +1.8% | 750,633 | -13.8% | 5.23% | +3.1% |
| Q2 2021 | $32,949,000 | +91.9% | 870,758 | +87.6% | 5.07% | +63.8% |
| Q1 2021 | $17,166,000 | +92.9% | 464,068 | +72.8% | 3.09% | +163.5% |
| Q4 2020 | $8,897,000 | – | 268,548 | – | 1.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |